ESR1 and prostate cancer: In this context, our current results suggest that based on the cell-dependent differential modulation of androgen actions by ER ligands and the elucidation of their molecular mechanisms, it would be possible to develop therapeutic agents that have great effects on prostate cancer with minimal cardiovascular side-effects.